This month we reviewed the research presented during the SGO and ASCO Annual Meetings. We had twenty-six participants and 1.2 million impressions. You may read our transcript here and analytics here.
Resources may be found at the end of the post.
T1: What #SGOMtg presentations did you personally find of most interest? Anything practice-changing?
- @SamBoseMD's study on RAD51 foci formation predicting DNA damage repair deficiency, and how PARP inhibitors may help more women with gyn #leiomyosarcoma
- I appreciated the study on older cervical cancer patients and how the current guidelines to stop screening after 65 are not working well in practice as there are conditions that need to be present to stop. https://www.cancertherapyadvisor.com/home/news/conference-coverage/society-of-gynecologic-oncology-sgo/sgo-2022/cervical-cancer-screening-guidelines-may-need-revision/
- For me Emeline Aviki's ,presentation on “Overspending on Dose-Specific Packaging of Lenvatinib for Endometrial Cancer,” which led to @EisaiUS announcing that it will expand its dose exchange program to cover dose reductions. https://www.sgo.org/news/eisai-adds-all-indicated-doses-to-lenvatinib-dose-exchange-program-after-research-presented-at-sgo-2022-annual-meeting/
- The ATHENA-MONO trial was very impressive - confirming benefit of #PARPi in the frontline maintenance setting for women with #OvarianCancer #ASCO22
- @NassifElise's presentation on the gut microbiome & response to #immunotherapy. Eat more fiber! (Unless you're prone to bowel obstructions)
- study done in Japan : bevacizumab (Avastin) added to first-line chemotherapy led to statistically significant improvements in PFS and (OS) in patients with advanced ovarian clear cell carcinoma (OCCC). Important those those with clear cell
- #ClinicalTrial examines combo #immunotherapy for #ovariancancer #gyncsm #ASCO22 #womenshealth https://www.uc.edu/news/articles/2022/06/trial-examines-combo-immunotherapy-for-ovarian-cancer.html
- For me ~ anything that involves #immunotherapy or #targetedtherapy is something I want to know more about in #cancer treatment
- There seems to finally be some great momentum around endometrial cancer and addressing disparities. That is exciting to see and long overdue
- Maximizing #treatment/#maintenance in HRD test negative #OvarianCancer remains a critical unmet need!
- Better understanding of how we can use molecular profiling in endometrial cancer to make treatment decisions is an important area of ongoing research. Where can we de-escalate treatment and who needs a more aggressive approach?
- Studies showing ethnic minorities, especially black women, are less likely to understand their prognosis, less likely to use hospice and more likely to end up in the ICU. We need better communication!
- Don’t be afraid to ask about #sexualhealth or body image concerns. We don’t talk about these issues enough and they are so common in the wake of cancer treatment.
- I saw a study on better genetic education for ovarian cancer patients, but I don't remember a lot of quality of life studies in general. It was nice to see emphasis on financial toxicity though.
- Genetics and genomics become more and more important for cancer patients to understand and advocate for treatment plans that include testing.
- COUNSELING! Diagnosis, treatment, aftercare, terminal care. It’s important for EVERYONE involved.
- @fumikochino has done great work in the area of financial toxicity.
- New Small Study finds virtual mindfulness-based intervention for sexual health as a feasible treatment option for #ovariancancer & #breastcancer survivors @NewsMedical #gyncsm #bcsm #womenshealth https://t.co/RZDW2qK9uA
- T5 Black cancer patients aren’t offered the chance at clinical trials--but over 80% would consider joining one if offered. #gyncsm #ASCO22 The survey was led by Stephanie Walker.
- The data on black patients and endometrial cancer is sobering. So was the ASCO study about black patients not being offered clinical trials. Look forward to seeing studies with practical steps and program models.
- #COVID-19 Outcomes in Patients With Gynecologic Cancer @CancerTherAdvsr #gyncsm #ASCO22 #womenshealth https://www.cancertherapyadvisor.com/home/news/conference-coverage/american-society-of-clinical-oncology-asco/asco-2022/covid-19-gynecologic-cancer-patient-outcomes/
T6: For our last topic, we'll let our participants ask any questions they have about recent gynecologic cancer research. Also, what do you want to see research resources focused on? Are there gaps in research you would like to see addressed?
- I'd like women with gyn #leiomyosarcoma who are treated in a private practice to know that they can get a second opinion from a #sarcoma medical oncologist. Collaboration helps patients know all of their options for treatment.
- T6 I heard about women having PARP resistance - like becoming platinum resistant. I wonder how many cycles of PARP does this start?
- https://www.lmsdr.org/ is partnering with @SARCtrials to help @JoannaPrzybyl with her research on ctDNA in #leiomyosarcoma. It would be great if ULMS could be better detected before surgery
- We are excited about our @MDAndersonNews #PARPi alone trial for women with #OvarianCancer that have #BRCA mutations and need neoadjuvant therapy! Data coming soon
We will not be chatting in July but we hope to see you on August 10, 2022 at 8pmET for our chat on Advocacy for Yourself and Others.
Have a safe July!
Dee and Christina
RESOURCES
Search Twitter for #SGOmtg #ASCO22 #gyncsm #leiomyosarcoma
SGO meeting :
@stigetta - https://ocrahope.org/2022/04/ovarian-cancer-highlights-society-of-gynecologic-oncology-meeting-2022/
ASCO Post https://ascopost.com/Meetings/?m=SGO+2022+Annual+Meeting+on+Women%E2%80%99s+Cancer
Cancer Network https://www.cancernetwork.com/conference/sgo
Cancer Therapy Advisor https://www.cancertherapyadvisor.com/home/news/conference-coverage/society-of-gynecologic-oncology-sgo/sgo-2022/
ASCO Meeting :
ASCO Abstracts https://conferences.asco.org/am/abstracts-posters
ASCO Post https://ascopost.com/Meetings/?m=2022+ASCO+Annual+Meeting
